April 1, 2022

Dr. Kelly Harms Named Lewis and Lillian Becker Professor of Dermatology

The Lewis and Lillian Becker Professorship in Dermatology was established through the generosity of Lewis and Lillian Becker to support a Dermatology faculty member engaged in research focusing on skin cancer epidemiology, therapy, education, and biology at Michigan Medicine.

smiling female physician
Kelly L Harms, MD PhD

Kelly L. Harms MD, PhD, Clinical Associate Professor of Dermatology was appointed as Lewis and Lillian Becker Professor of Dermatology on April 1, 2022. Dr.  Harms graduated with her MD and PhD from the Medical Scientist Training Program at the University of Alabama at Birmingham Medical School. At Michigan Medicine, she completed her internship in the Department of Internal Medicine, followed by dermatology residency and post-doctoral training in skin cancer research (NIH T32 fellow) and a Mohs micrographic surgery clinical fellowship in the Department of Dermatology.
She joined the Department of Dermatology Mohs surgery faculty as Clinical Lecturer in 2014, became Clinical Assistant Professor in 2015, and was promoted to Clinical Associate Professor in 2021. Dr. Harms serves as Chief of the Cutaneous Surgery and Oncology Division and Medical Director of the Mohs Ambulatory Care Clinic. Additionally, she directs the Multidisciplinary Cutaneous Oncology Program at the Rogel Cancer Center and is Assistant Program Director for the Micrographic Surgery and Dermatologic Oncology Fellowship.
An internationally recognized expert in the field of Merkel cell carcinoma (MCC), Dr. Harms’ research focuses on improving diagnosis, prognostication, and management for this rare and aggressive form of skin cancer.  She has published over 25 peer-reviewed articles and has presented her work at institutions and conferences throughout the U.S. and abroad. As a member of the National Comprehensive Cancer Network Panel on Non-melanoma Skin Cancer, she is helping to shape national guidelines for the management of complex cutaneous malignancies, including MCC and other high-risk skin cancers.